Presenting at a Key Conference
Arbutus Biopharma Corporation (NASDAQ: ABUS), a leading clinical-stage biopharmaceutical company specializing in the treatment of chronic hepatitis B virus (cHBV) infections, is poised to make an important presentation at an upcoming vital investor conference. Set for October 8, this event will feature a fireside chat at 1:30 pm ET, accompanied by one-on-one meetings with investors, offering a profound opportunity to share groundbreaking information regarding their therapeutic advancements.
Fireside Chat Insights
The forthcoming fireside chat will be an engaging experience, highlighting Arbutus’s innovative approach in the quest for a functional cure for cHBV. Attendees can expect discussions focused on the latest developments related to their promising pipeline and how these efforts can significantly improve treatment protocols for patients suffering from this chronic condition.
About Arbutus Biopharma
Arbutus Biopharma Corporation is recognized for its deep virology expertise, which it applies in developing pioneering therapeutics targeting hepatitis B. The company’s research emphasizes the importance of suppressing HBV DNA, reducing surface antigen levels, and enhancing HBV-specific immune responses as key components to reaching therapeutic goals.
Innovative Therapeutics in Development
Arbutus has developed a robust pipeline that includes groundbreaking treatments such as imdusiran (AB-729), an RNAi therapeutic, and AB-101, an oral PD-L1 inhibitor—the latter currently undergoing evaluation in a Phase 1a/1b clinical trial. Imdusiran has generated encouraging clinical results, notably in reducing surface antigen levels and revitalizing the immune response specifically against HBV. This combination of therapies marks a highly strategic effort to provide a more effective treatment course for patients.
Engaging with the Community
The October conference represents an essential touchpoint for Arbutus, as it allows the company to foster relationships with investors and industry stakeholders. By sharing their innovative research and successful clinical data, Arbutus aims to increase awareness and support for its mission to address the unmet medical need in chronic hepatitis B treatment.
Future Prospects for Patients
Given the challenges presented by chronic hepatitis B, advancements by companies like Arbutus provide hope for patients who are seeking more effective treatment options. With the ongoing trials and research into therapeutics showing significant promise, the industry is poised for potentially transformative developments.
Contact Information
For further inquiries, investors and media representatives can reach out to:
Lisa M. Caperelli
Vice President, Investor Relations
Phone: 215-206-1822
Email: lcaperelli@arbutusbio.com
Frequently Asked Questions
What is the focus of Arbutus Biopharma?
Arbutus Biopharma focuses on developing innovative treatments for chronic hepatitis B virus infections, aiming for a functional cure.
What is imdusiran?
Imdusiran (AB-729) is an RNAi therapeutic developed by Arbutus that has shown promising results in reducing viral surface antigens and enhancing immune responses.
When is the presentation taking place?
The presentation at the H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference will occur on October 8 at 1:30 pm ET.
How can I access the fireside chat?
To access the live webcast of the fireside chat, you can visit the Arbutus investor relations page, where a replay will also be available after the event.
Who can I contact for more information?
For inquiries, you can contact Lisa M. Caperelli, the Vice President of Investor Relations at Arbutus, via phone or email.
